Cystatin E/M suppresses legumain activity and invasion of human melanoma

被引:60
作者
Briggs, Jon J. [2 ]
Haugen, Mads H. [2 ]
Johansen, Harald T. [1 ]
Riker, Adam I. [3 ]
Abrahamson, Magnus [4 ]
Fodstad, Oystein [2 ,5 ]
Maelandsmo, Gunhild M. [2 ]
Solberg, Rigmor [1 ]
机构
[1] Univ Oslo, Dept Pharmaceut Biosci, Sch Pharm, N-0316 Oslo, Norway
[2] Oslo Univ Hosp, Dept Tumor Biol, Inst Canc Res, Oslo, Norway
[3] Ochsner Med Ctr, Ochsner Canc Inst, New Orleans, LA USA
[4] Lund Univ, Dept Lab Med, Div Clin Chem Pharmacol, S-22100 Lund, Sweden
[5] Univ Oslo, Radiumhosp Fac Div, Fac Med, N-0316 Oslo, Norway
来源
BMC CANCER | 2010年 / 10卷
基金
瑞典研究理事会;
关键词
CYSTEINE PROTEINASE-INHIBITOR; ABERRANT DNA METHYLATION; CATHEPSIN-B ACTIVITY; CANCER CELL-LINE; BREAST-CANCER; MAMMALIAN LEGUMAIN; TUMOR PROGRESSION; GENE-EXPRESSION; EPIDERMAL DIFFERENTIATION; M/E EXPRESSION;
D O I
10.1186/1471-2407-10-17
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: High activity of cysteine proteases such as legumain and the cathepsins have been shown to facilitate growth and invasion of a variety of tumor types. In breast cancer, several recent studies have indicated that loss of the cysteine protease inhibitor cystatin E/M leads to increased growth and metastasis. Although cystatin E/M is normally expressed in the skin, its role in cysteine protease regulation and progression of malignant melanoma has not been studied. Methods: A panel of various non-melanoma and melanoma cell lines was used. Cystatin E/M and C were analyzed in cell media by immunoblotting and ELISA. Legumain, cathepsin B and L were analyzed in cell lysates by immunoblotting and their enzymatic activities were analyzed by peptide substrates. Two melanoma cell lines lacking detectable secretion of cystatin E/M were transfected with a cystatin E/M expression plasmid (pCST6), and migration and invasiveness were studied by a Matrigel invasion assay. Results: Cystatin E/M was undetectable in media from all established melanoma cell lines examined, whereas strong immunobands were detected in two of five primary melanoma lines and in two of six lines derived from patients with metastatic disease. Among the four melanoma lines secreting cystatin E/M, the glycosylated form (17 kD) was predominant compared to the non-glycosylated form (14 kD). Legumain, cathepsin B and L were expressed and active in most of the cell lines, although at low levels in the melanomas expressing cystatin E/M. In the melanoma lines where cystatin E/M was secreted, cystatin C was generally absent or expressed at a very low level. When melanoma cells lacking secretion of cystatin E/M were transfected with pCST6, their intracellular legumain activity was significantly inhibited. In contrast, cathepsin B activity was not affected. Furthermore, invasion was suppressed in cystatin E/M over-expressing melanoma cell lines as measured by the transwell Matrigel assay. Conclusions: These results suggest that the level of cystatin E/M regulates legumain activity and hence the invasive potential of human melanoma cells.
引用
收藏
页数:13
相关论文
共 57 条
  • [51] Legumain from bovine kidney: its purification, molecular cloning, immunohistochemical localization and degradation of annexin II and vitamin D-binding protein
    Yamane, T
    Takeuchi, K
    Yamamoto, Y
    Li, YH
    Fujiwara, M
    Nishi, K
    Takahashi, S
    Ohkubo, I
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2002, 1596 (01): : 108 - 120
  • [52] Yan SQ, 1998, BIOL CHEM, V379, P113
  • [53] Epidermal differentiation: The role of proteases and their inhibitors
    Zeeuwen, PLJM
    [J]. EUROPEAN JOURNAL OF CELL BIOLOGY, 2004, 83 (11) : 761 - 773
  • [54] Cystatin M/E expression in inflammatory and neoplastic skin disorders
    Zeeuwen, PLJM
    Van Vlijmen-Willems, IMJJ
    Egami, H
    Schalkwijk, J
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (01) : 87 - 94
  • [55] Cystatin M/E expression is restricted to differentiated epidermal keratinocytes and sweat glands: a new skin-specific proteinase inhibitor that is a target for cross-linking by transglutaminase
    Zeeuwen, PLJM
    van Vlijmen-Willems, IMJJ
    Jansen, BJH
    Sotiropoulou, G
    Curfs, JH
    Meis, JFGM
    Janssen, JJM
    van Ruissen, F
    Schalkwijk, J
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 116 (05) : 693 - 701
  • [56] Cystatin M: A novel candidate tumor suppressor gene for breast cancer
    Zhang, J
    Shridhar, R
    Dai, Q
    Song, J
    Barlow, SC
    Yin, LJ
    Sloane, BF
    Miller, FR
    Meschonat, C
    Li, BDL
    Abreo, F
    Keppler, D
    [J]. CANCER RESEARCH, 2004, 64 (19) : 6957 - 6964
  • [57] Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer
    Zhong, S.
    Fields, C. R.
    Su, N.
    Pan, Y-X
    Robertson, K. D.
    [J]. ONCOGENE, 2007, 26 (18) : 2621 - 2634